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unable to determine the proportion of AMI acute myocardial
infarction (AMI) patients eligible for enrollment in the study.
Dr. Silverman questioned the safety of transfer of the AMI
patient. Although his concerns are valid, all emergency medical
systems that would be transferring AMI patients are trained in
advanced cardiac life support. These systems should be able to
resuscitate AMI patients, as well as the staff in the emergency
department or intensive care units of small hospitals.
In fact, five randomized trials of transfer for primary angioplasty
have shown that transfer is safe and is associated with better
outcomes compared to on site thrombolytics (1–5) (Table 1).
Experienced angioplasty operators may safely perform primary
angioplasty in diagnostic catheterization laboratories. However,
the expense of training staff, both in the laboratory and in recovery
units, in addition to stocking expensive angioplasty equipment,
may not be feasible in small hospitals.
Finally, it would be far easier to instruct emergency medical staff
drivers to head in the correct direction—toward a primary angio-
plasty facility.
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Possible Risks to Patients Receiving
Statins Combined With Other Medications
The American College of Cardiology/American Heart Associa-
tion/National Heart Lung, and Blood Institute (ACC/AHA/
NHLBI) Clinical Advisory on Statins (1) was a timely review of an
important issue, but I believe that additional information on the
issue of drug interactions would be helpful to clinicians who
manage patients receiving statins with other medications.
First, as for combining statins with CYP3A4 inhibitors, only
lovastatin and simvastatin undergo extensive (90% or more)
presystemic metabolism by CYP3A4 in the gut wall and liver (2).
Hence, the risk of statin-induced myopathy due to CYP3A4
inhibitors appears to be considerably greater for lovastatin and
simvastatin compared to the other statins. For example, potent
CYP3A4 inhibitors such as itraconazole can produce 10- to
20-fold increases in the serum concentrations of lovastatin or
simvastatin (3,4). Atorvastatin is also metabolized by CYP3A4,
but it does not undergo as extensive presystemic metabolism as
lovastatin and simvastatin. Accordingly, potent CYP3A4 inhibi-
tors tend to produce two- to four-fold increases in atorvastatin
serum concentrations (5,6). Pravastatin is not metabolized by
CYP3A4 or other cytochrome P450 isozymes, and inhibition of
CYP3A4 has little effect on its pharmacokinetics (4,6). Fluvastatin
is metabolized primarily by CYP2C9 and also is unlikely to
interact with CYP3A4 inhibitors (2).
Second, as for macrolides and statins, erythromycin and clar-
ithromycin are correctly listed as potentially increasing the risk of
statin-associated myopathy. As described above, this caution re-
sults from the ability of these two macrolide antibiotics to inhibit
the CYP3A4 metabolism of lovastatin, simvastatin, and to a lesser
extent atorvastatin (7,8). But a separate bullet point lists “Macro-
lide antibiotics” (page 571 under “Prevention” heading). This
might lead some readers to conclude that azithromycin and
dirithromycin interact with statins, but substantial evidence sug-
gests that these macrolides do not inhibit CYP3A4 (9).
Finally, as for the interaction of calcium-channel blockers and
statins, verapamil—a known CYP3A4 inhibitor—is listed as
increasing the risk of statin-associated myopathy, but diltiazem is
not mentioned. Available evidence suggests that verapamil and
diltiazem are roughly equivalent (moderate) inhibitors of
CYP3A4. Indeed, diltiazem has been shown in pharmacokinetic
studies to increase serum concentrations of both lovastatin and
simvastatin (10,11), and isolated cases of myopathy have been
reported in patients receiving simvastatin plus diltiazem (12,13).
Table 1. Pooled Outcomes From Five Studies of Transfer for Primary PTCA Versus On Site:
Lytics
PCI Lytic p Value
Odds
Ratio 95% CI
Death 103/1,468 (7.0%) 129/1,443 (8.9 %) 0.055 1.3 0.99–1.70
Nonfatal reMI 19/1,037 (1.8%) 68/1,022 (6.7 %)  0.0001 3.82 2.28–6.40
Total stroke 11/1,037 (1.1%) 22/1,022 (2.2 %) 0.049 2.05 0.99–4.25
Death/stroke/MI 121/1,468 (8.2%) 217/1,443 (15.0%)  0.0001 1.97 1.56–2.49
CI  confidence interval; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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The available evidence would thus suggest that the risk of adding
verapamil or diltiazem to simvastatin or lovastatin is roughly
equivalent. Conversely, calcium-channel blockers such as amlodip-
ine, felodipine, and nifedipine have not been shown to inhibit
CYP3A4 significantly.
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